Allist Pharmaceuticals, Inc.
Clinical trials sponsored by Allist Pharmaceuticals, Inc., explained in plain language.
-
New hope for Tough-to-Treat lung cancer mutation
Disease control OngoingThis early-stage study is testing a drug called furmonertinib for people with advanced non-small cell lung cancer that has a specific genetic mutation called EGFR exon 20 insertion. The trial will enroll 30 people to see if the drug is safe and can help shrink or control their tu…
Phase: PHASE1 • Sponsor: Allist Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New Two-Drug attack targets Tough-to-Treat cancers
Disease control OngoingThis study is testing a new oral drug, JAB-21822, combined with an existing cancer drug called cetuximab. It is for people with advanced colorectal, small intestine, or appendix cancers that have a specific genetic change called KRAS G12C. The main goals are to find a safe and ef…
Phase: PHASE1, PHASE2 • Sponsor: Allist Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New targeted drug shows promise against Tough-to-Treat cancers
Disease control OngoingThis study is testing an experimental drug called JAB-21822 (glecirasib) for people with advanced cancers that have a specific genetic change called KRAS G12C mutation. The trial aims to find the safest and most effective dose while checking if the drug can shrink tumors. It incl…
Phase: PHASE1, PHASE2 • Sponsor: Allist Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New hope for Tough-to-Treat lung cancer mutation
Disease control OngoingThis study is testing an oral drug called furmonertinib for adults with advanced non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion) and has worsened after standard chemotherapy. The main goal is to see if the drug can shrink tumors and control …
Phase: PHASE2 • Sponsor: Allist Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC